Your browser doesn't support javascript.
loading
Semaglutide treatment attenuates vessel remodelling in ApoE-/- mice following vascular injury and blood flow perturbation.
Jensen, Ditte Marie; Skovsted, Gry Freja; Bonde, Mathilde Frederikke Bjørn; Bentzon, Jacob Fog; Rolin, Bidda; Franck, Grégory; Ougaard, Maria Katarina Elm; Voetmann, Louise Marie; Bachmann, Julian Christoffer; Uryga, Anna; Pyke, Charles; Kirk, Rikke Kaae; Hvid, Henning; Knudsen, Lotte Bjerre; Lykkesfeldt, Jens; Nyberg, Michael.
Afiliación
  • Jensen DM; Department of Veterinary and Animal Sciences, University of Copenhagen, Ridebanevej 9, 1870 Frederiksberg C, Copenhagen, Denmark.
  • Skovsted GF; Research and Early Development, Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark.
  • Bonde MFB; Department of Veterinary and Animal Sciences, University of Copenhagen, Ridebanevej 9, 1870 Frederiksberg C, Copenhagen, Denmark.
  • Bentzon JF; Research and Early Development, Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark.
  • Rolin B; Department of Clinical Medicine, Heart Diseases and Steno Diabetes Center Aarhus, Palle Juul-Jensens Boulevard 99, Aarhus University, 8200, Aarhus, Denmark.
  • Franck G; Centro Nacional de Investigaciones Cardiovasculares (CNIC), Alle Melchor Fernandez Almagro, 3, 28029, Madrid, Spain.
  • Ougaard MKE; Research and Early Development, Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark.
  • Voetmann LM; INSERM U1148, Laboratory for Vascular Translational Science, Bichat Hospital, 46 Rue Henri Huchard, Paris, France.
  • Bachmann JC; Research and Early Development, Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark.
  • Uryga A; Research and Early Development, Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark.
  • Pyke C; Research and Early Development, Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark.
  • Kirk RK; Research and Early Development, Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark.
  • Hvid H; Research and Early Development, Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark.
  • Knudsen LB; Research and Early Development, Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark.
  • Lykkesfeldt J; Research and Early Development, Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark.
  • Nyberg M; Research and Early Development, Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark.
Atheroscler Plus ; 49: 32-41, 2022 Aug.
Article en En | MEDLINE | ID: mdl-36644202
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Atheroscler Plus Año: 2022 Tipo del documento: Article País de afiliación: Dinamarca Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Atheroscler Plus Año: 2022 Tipo del documento: Article País de afiliación: Dinamarca Pais de publicación: Países Bajos